Spearhead Capital Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Spearhead Capital Advisors’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,198	Closed	-$256K	–	207
2022 Q1	$256K	Sell	2,198 -2,423	-52%	-$283K	0.03%	161
2021 Q4	$696K	Buy	4,621 +35	+0.8%	+$4.72K	0.08%	78
2021 Q3	$547K	Sell	4,586 -16	-0.3%	-$1.76K	0.07%	87
2021 Q2	$448K	Buy	4,602 +567	+14%	+$50.6K	0.06%	127
2021 Q1	$356K	Buy	4,035 +795	+25%	+$73.9K	0.05%	118
2020 Q4	$310K	Buy	3,240 +147	+5%	+$15.2K	0.05%	138
2020 Q3	$351K	Buy	3,093 +179	+6%	+$18.8K	0.07%	110
2020 Q2	$288K	Buy	+2,914	New	+$233K	0.06%	110

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Spearhead Capital Advisors's TNDM Position: Q2 2022 in Review

Spearhead Capital Advisors sold out of Tandem Diabetes Care (TNDM) in Q2 2022, closing a stake of 2,198 shares — an estimated $256K sold.

Spearhead Capital Advisors first reported a position in TNDM in Q2 2020 and held it in 8 quarters. The position peaked at $696K in Q4 2021. 330 funds tracked by Wall St. Rank hold TNDM as of Q2 2022.

Spearhead Capital Advisors reported no remaining Tandem Diabetes Care position as of Q2 2022 after selling out during the quarter.
Spearhead Capital Advisors sold 2,198 Tandem Diabetes Care shares in Q2 2022, an estimated $256K.
Spearhead Capital Advisors first reported a position in Tandem Diabetes Care in Q2 2020 and held it in 8 quarters.
Spearhead Capital Advisors's Tandem Diabetes Care position peaked at $696K in Q4 2021.
330 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2022.

Based on Spearhead Capital Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.